Accountable care organizations (ACOs) are of 2 minds right now. On the one hand, there is a lot of excitement for the future of ACOs, but there is also great anxiety around the changes that CMS proposed for the Medicare Shared Savings Program (MSSP), said Clif Gaus, ScD, president and CEO of the National Association of ACOs (NAACOS).
Accountable care organizations (ACOs) are of 2 minds right now. On the one hand, there is a lot of excitement for the future of ACOs, but there is also great anxiety around the changes that CMS proposed for the Medicare Shared Savings Program (MSSP), said Clif Gaus, ScD, president and CEO of the National Association of ACOs (NAACOS).
Transcript
What were some of the key takeaways from the NAACOS fall 2018 meeting?
I would say there are a couple, in addition to breaking our own record with attendance, and I would say the level of excitement here is as high as I’ve seen around our future, but the anxiety is probably as high as I’ve ever seen because of the proposed changes that CMS is proposed to make [to MSSP].
I’m confident, I guess, that we’ll see some give on their part, particularly around the speed that they’re asking us to move to risk, and particularly around the reduction in shared savings. I’m quoted in other places as saying, “there’s a carrot and a stick, and what they proposed to do is cut the carrot in half.” And going from 50% savings shared with the ACO to 25% is a dramatic decline and that would affect the new ACOs coming into the program in 2019 and 2020.
So, we’re hopeful they’ll both adjust that speed to risk and the shared savings amount—go back to the 50%. We see that as a minimum to engage the hospitals and doctors in what is an expensive undertaking for them. Our estimates are at least $1 million a year in infrastructure for an ACO, on average, and that includes hiring the care coordinators, that includes all the information systems, and medical systems. So, they’re not going to make that kind of investment out of their own pockets, if there’s not some hope that they’ll achieve savings and get paid back for that.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More